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Abstract
Background Immune-mediated scleritis is a rare condition,
and the information on the clinical course and complications
is scarce. The aim of this study was to identify prognostic
factors, complications, and therapeutic effects in patients with
immune-mediated scleritis.
Methods Patients with diagnosis of scleritis and a follow-up
time of 5 years were identified. Systemic disease, laboratory
investigations, type of scleritis, disease activity, therapy, and
complications were recorded. The study design was a retro-
spective, non-comparative, interventional case series.
Results Systemic disease was identified in 15 (37 %) patients
at presentation and in 18 (45 %) after 5 years. Rheumatoid
arthritis (15 %), granulomatosis with polyangiitis (7.5 %), and
polychondritis (7.5 %) were the most predominant disorders.
Persistent scleritis (>5 years) was associated with systemic
disease (66 vs. 6 %; p<0.05) and positive auto-antibodies (48
vs. 23 %; p=0.18). Control of ocular inflammation was
achieved in 38 of 40 (95 %). Prednisone (14 patients) and/or
methotrexate (8) were the predominant drugs to control per-
sistent disease. Complications included interstitial keratitis
(2), inflammatory astigmatism (2), corneal melt (3), macular
edema (6), and severe systemic disease (5).
Conclusion The presence of systemic disease and positive
auto-antibodies are associated with persistent scleritis. Immu-
nosuppressive agents allow control of scleritis, but may con-
tribute to severe systemic complications.
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Introduction
Scleritis often occurs as a chronic inflammatory process.
Although in some instances it may be caused directly by an
infective agent, the vast majority of cases present as an
immune-mediated disorder [1–3]. Immune-mediated scleritis
may be associated with systemic disease. Usually systemic
therapy is required to control inflammation. Morphologic
criteria are used to classify scleral inflammation clinically into
anterior and posterior types [3]. Anterior scleritis is
subclassified into diffuse, nodular, necrotising with inflamma-
tion, and necrotising without inflammation (scleromalacia).
Little information on the clinical course and complications
of scleritis is available [4–7]. This study aims to gain knowl-
edge on the long-term outcome of scleritis, and to identify
prognostic factors. This was done by studying systemic dis-
ease and laboratory findings, and by the assessment of com-
plications and therapeutic effects.
Patients and methods
In 2010 we reviewed the records of more than 100 patients
who were referred to our institution with the diagnosis "scleral
inflammation". Forty patients and 56 affected eyes with diag-
nosis of immune-mediated scleritis and the possibility to be
followed by our team for the next 5 years were identified and
investigated. After having obtained informed consent, these
patients were included in the study. The demographic data are
shown in Table 1. Immune-mediated scleritis was diagnosed
on clinical grounds (constant and nocturnal pain with spread-
ing to the periorbital region, scleral edema, tenderness of the
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globe, presence of nodules, or signs of scleral necrosis), and
was supported in two cases by tissue examination (absence of
infective agents). Patients with superficial inflammation (rath-
er episcleritis than scleritis), infectious scleritis, neoplastic
lesions, and/or incomplete data were excluded. A standardised
protocol was used to record systemic disease, laboratory in-
vestigations, type of scleritis, disease activity, therapy, and
complications (Table 2). The duration of scleritis was deter-
mined as abscence of clinical inflammation for more than
6 months after stopping therapy (local and systemic).
For the treatment of scleritis, an anti-inflammatory strategy
was applied as published elsewhere [8]. For non-necrotising
scleritis oral nonsteroidal anti-inflammatory drugs such as
flurbiprofen (100–300 mg/24 h), sometimes in combination
with steroids, were used to induce remission. For consolida-
tion, methotrexate, azathioprine, anti-TNF-alpha blockers or
cyclosporine were applied. Necrotising scleritis was treated
with high-dose oral prednisone or intravenous methylprednis-
olone in combination with cyclophosphamide. Cyclophospha-
mide was given parenterally in an initial phase, later per os.
Posterior scleritis was treated in this series solely with oral
prednisone. All medication was given according to the guide-
lines of the RheumatologyDepartment, University Hospital of
Zürich (Head Prof. Beat Michel) and supervised by experi-
enced rheumatologists. Successful medical control of disease
was defined as absence of symptoms, clinical inflammation
and, in necrotising disease, halt of further tissue destruction.
The contingency table (see Table 6) was analysed using
Fisher’s exact test. Patients with persistent scleritis (more than
5 years of ongoing scleral inflammation) were compared with
patients who showed a shorter course of scleral inflammation.
Results
The median age at first presentation was 51 years, and 65 %
were females. In 37.5 % (15 patients), a systemic disorder was
already known at presentation; in the further course the figure
raised to 45 % (18). Rheumatoid arthritis was the most fre-
quent systemic disease (15 % or six patients), followed by
polychondritis in three, and granulomatosis with polyangiitis
(GPA) in three patients (Table 3). The type of scleritis at
presentation is shown in Table 4: Non-necrotising anterior
scleritis was the most frequent type (77.5 %, 31 eyes).
Necrotising anterior scleritis was seen in five and posterior
inflammation in six eyes. Two eyes had both inflammation of
the anterior and posterior segments. In 26 out of 40 patients,
the scleritis stayed unilateral. In four patients, however, scleral
inflammation became bilateral (Table 5). During follow-up,
the type of scleritis changed in four patients; one patient who
had initially presented with anterior disease developed poste-
rior scleritis. One patient with initial posterior disease
Table 1 Demographic data
Age at presentation (median) 51 years (range 31–74)
Females/males 65 %/35 %
Relative and absolute number of patients
at follow-up (months)
100 % (40) at 12
95 % (38) at 36
95 % (38) at 60
55 % (18) at 120 months
Deceased (relative and absolute number
of cases at follow-up in months)
5 % (2) 12–60
17.5 % (7) 61-120
Table 2 Protocol for the investigation of scleritis patients
Systemic disease
Laboratory investigations (serum rheumatoid factor, ANA, ANCA)
Type of scleritis
Disease activity at presentation, 12, 36, 60, and 120 months
Therapy
Complications
Table 3 Association of scleritis with systemic disease
At first presentation: 37.5 % (15)
During the further course: 45 % (18)
Rheumatoid arthritis 15 % (6)
Polychondritis 7.5 % (3)
Granulomatosis with polyangiitis
(formerly Wegener’s granulomatosis)
7.5 % (3)
Polyarteritis nodosa 2.5 % (1)
HLA-B27 positive (ankylosing) spondylitis 2.5 % (1)
HLA-B27 negative spondylitis 2.5 % (1)
Scleroderma 2.5 % (1)
Colitis ulcerosa 2.5 % (1)
Cogan’s syndrome 2.5 % (1)
Table 4 Type of scleritis at presentation
Unilateral Bilateral
Diffuse/nodular 77.5 % (31) 45 % (18) 32.5 % (13)
Necrotising 12.5 % (5) 12.5 % (5) 0
with inflammation 7.5 % (3) 7.5 % (3)
without inflammation 5 % (2) 5 % (2)
Posterior 15 % (6) 7.5 % (3) 7.5 % (3)
Totala 62 % (26)a 38 % (16)a
a Two eyes with anterior and posterior inflammation
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developed non-necrotising anterior scleritis 2 years later. Two
patients with non-necrotising inflammation at first visit devel-
oped ischemic areas, thus necrotising scleritis (Fig. 1).
In 21 out of 40 patients (52 %) scleral inflammation lasted
more than 5 years. This persistant scleritis (more than 5 years
ongoing scleral inflammation) was associated with systemic
disease (14/21 in comparison to 1/17 patients with shorter
inflammation episodes). This association was statistically sig-
nificant when analysed by Fisher’s exact test. The presence of
positive circulating antibodies (10/21 versus 4/17) showed a
trend to favour persistent inflammation. This is shown in
Table 6.
Information on the medical control of scleral inflammation
is given in Tables 7 and 8. Control of scleritis was achieved in
38 out of 40 patients. In two patients with necrotising scleritis,
the loss of scleral tissue could not be halted. One of these
patients, a 75-year-old male, developed stomach carcinoma
and therapy with cyclophosphamide was subsequently
stopped. This patient died 18 months after first presentation.
The other patient, a 39-year-old female with severe rheuma-
toid arthritis, developed ongoing scleromalacia despite immu-
nosuppression with oral steroids, cyclophosphamide and
TNF-alpha-blockade (Figs. 2 and 3).
The complications of scleral disease are listed in Table 9.
Corneal complications included interstitial keratitis (two eyes),
peripheral corneal melts (three eyes) and scleritis-induced
astigmatism (two eyes) (Fig. 4, Table 10). Six patients devel-
oped cystoid macular edema. In two patients the scleritis had
led to persistent structural damages and functional loss (long-
standing retinal detachments without light perception). Several
patients developed severe systemic disease: myocardial
infarction at age 44 and IgA-nephropathy, pericarditis with
valvular and coronary heart disease (possibly associated with
the polyarteritis nodosa), and two patients died within the 5-
year follow-up period (Table 11).
Discussion
Information on the outcome of scleritis is scarce. To date, there
are case reports and the Moorfields, Boston, and Baltimore
cohorts [1, 3, 6] that help to understand the nature of scleral
inflammation. Our study sets the focus on the long-term
course of scleritis and, in this way, teaches us about the
outcome of immune-mediated scleritis.
Scleritis is a potentially long-lasting problem. Fifty-two
percent of our patients showed a disease duration of more
than 5 years. Although this figure may be biased by the fact
that we see patients as tertiary referrals, we were surprised by
this high number. An underlying systemic disease and positive
autoantibodies were identified as risk factors for such a long
disease duration.
Melts, interstitial keratitis, and peripheral ulcerative kerati-
tis are well known corneal complications of scleritis [4–7].
Inflammatory astigmatism due to scleritis was previously
described [9, 10], but none of those patients had such a high
cylinder measurement as our patient with 8.5 diopters (Ta-
ble 10). A second patient of our series had a cylinder mea-
surement of 2.5 diopters. In both patients it was reversible
after remission of scleritis. We feel that it is the increase in
Table 5 Scleritis course
(0–60 months) Unilateral→ bilateral 4
Changing type of scleritis 4
Anterior→ Posterior 1
Posterior→ Anterior 1
Nodular/diffuse→ Necrotising 2
Fig. 1 patient with non-necrotising at first visit developed ischemic
areas, thus necrotising scleritis
Table 6 Duration of scleritis
<5 years >5 years p value*
Percentage (effective) 43 % (17) 52.5 % (21)
Systemic disease 1/17 14/21 < 0.05
Autoantibodies 4/17 10/21 0.18
Serum rheumatoid factor
(ELISA >25mu/ml)
2 7
ANA (Titer, >1:10) 2 5
ANCA (Titer, >1:10) 0 3
No clinical inflammation for >6 months after stopping therapy (local and
systemic)
*p by Fisher’s exact test
Table 7 Medical control of disease activity
Yes No
Control of inflammation 38 2a
No discomfort, no further destruction
a Ongoing destruction in the two patients with scleromalacia
Graefes Arch Clin Exp Ophthalmol (2014) 252:1477–1481 1479
Fig. 4 A 73-year-old female who developed anterior and posterior non-
necrotizing scleritis. The scleral nodule in the upper and nasal quadrants
resulted in a corneal astigmatism of −8.50 in 117°. The course of the
corneal curvature is shown in Table 10
Table 10 Corneal astigmatism before and after onset of anterior non-
necrotizing scleritis which responded to treatment with oral steroids. The
affected eye is shown in Fig. 4
Follow-up time Autorefraction (NIDEK ARK-700A)
Pre-inflammatory refraction −3.50 −1.25 110°
Day 1 a −8.50 117°
Day 14 −1.00 −6.00 110°
Day 28 −1.75 −4.50 116°
Day 42 −1.50 −4.25 113°
Day 90 −0.75 −3.75 111°
Day 120 −1.00 −3.75 111°
a Sphere not measurable
Table 9 Complications (months 0–60)
Interstitial keratitis 2
Scleritis-induced astigmatism 2
Peripheral corneal melt 3
Cystoid macular edema 6
Persistent structural damage→ enucleation 2
Severe systemic disease 5
Myocardial infarction at age 44, IgA-nephropathy 1
Pericarditis, valvular/coronary heart disease 1
Deceased (patients #5 and #6)* 2
*For details of these patients see Table 11
Fig. 3 The same eye as in Fig. 2. The progression over a period of 5 years
is obvious
Fig. 2 Scleromalacia in a 39-year-old female with severe rheumatoid
arthritis. There is progressive scleral destruction despite immunosuppres-
sion with oral steroids, cyclophosphamide, and TNF-alpha blockade
Table 8 Systemic medication in 40 scleritis patients
0–1 months 12 months 36 months
NSAID 20 10 3
Prednisone 21 22 14
Cyclophosphamide 5 3 –
Methotrexate 5 6 8
Azathioprine 2 1 1
Anti-TNF-alpha
Infliximab (Remicade ®) 1
Adalimumab (Humira ®) 1 1
Cyclosporine A 1 1
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volume of the inflamed sclera that leads to changes of scleral
rigidity with subsequent instability of limbal contour and
corneal steepening in the affected quadrant.
Macular edema was observed in 11 % of our patients.
When detected at an early stage it was fully reversible after
high-dose oral steroids. One of our patients presented with
posterior scleritis only and developed anterior scleritis years
later in the same eye, and three other eyes changed the type of
scleritis (Table 5). This is in contrast to Tuft’s study [11] who
found that the majority of patients remain in the same clinical
category. It seems that a change in the scleritis pattern is not
unusual when patients are available for long-term follow-up.
The evaluation of the best medication for the treatment of
scleritis was beyond the scope of this study. With the correct
application of traditional and new generation immunosup-
pressive agents, preferably in collaboration with a rheuma-
tologist, disease control is possible in most cases. In our
series, remission was achieved in 95 %. In one patient with
long-standing rheumatoid arthritis and scleromalacia (Figs. 2
and 3), tissue loss could not be halted despite application of
TNF-alpha blockers and, at a later stage, cyclophosphamide
in combination with oral steroids. This demonstrates again
that this vasculitic complication is particularly difficult to
tackle [1, 6, 7].
Our patients showed a considerable morbidity and a high
number of lethal complications. Five percent of our patients
died within 5 years and 17.5 % within 10 years of follow-up
time. Three of the deaths were older than 75 years and pre-
sumably died of natural causes. Of concern are the two pa-
tients who died with aplastic anemia and septicemia. This
demonstrates that the immunosuppressive therapies have the
potential to cause lethal complications, although the systemic
disease itself may be life-threatening [1, 2]. New agents allow
control of scleritis, but may also contribute to systemic
complications.
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Table 11 Deaths (0–120 months)
Patient Cause of death Type and duration
of scleritis (months)
Systemic
inflammatory disease
Systemic medication
C.A., ♂, age 76 years, # 5 Stomach carcinoma Necrotising, 9 Steroids, cyclophosphamide
E.M.,♀, age 68 years, #6 Not known Anterior and posterior,> 60 Steroids, azathioprine
E.W., ♂, age 72 years, # 7 Aplastic anemia Necrotising, 38 Rheumatoid arthritis Steroids, methotrexate,
cyclophosphamide,
later azathioprine
H.HR., ♂, age 45 years, # 12 Sepsis (immunosuppression?) Diffuse anterior, 120 Polychondritis Steroids, infliximab
K. H., ♂, age 70 years, #13 Renal failure Diffuse anterior, 21 Polychondritis Steoids, cyclosporine
L. M., ♀, age 80 years, # 17 Heart failure Diffuse anterior, 15 Cogan’s syndrome Steroids, cyclophosphamide
S.F., ♂, age 79 years, # 26 Aortic aneurysm Necrotising, 9 Steroids, cyclophosphamide
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